Last reviewed · How we verify
Adipose tissue-derived mesenchymal stem cells — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Adipose tissue-derived mesenchymal stem cells (Adipose tissue-derived mesenchymal stem cells) — Rigshospitalet, Denmark.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adipose tissue-derived mesenchymal stem cells TARGET | Adipose tissue-derived mesenchymal stem cells | Rigshospitalet, Denmark | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adipose tissue-derived mesenchymal stem cells CI watch — RSS
- Adipose tissue-derived mesenchymal stem cells CI watch — Atom
- Adipose tissue-derived mesenchymal stem cells CI watch — JSON
- Adipose tissue-derived mesenchymal stem cells alone — RSS
Cite this brief
Drug Landscape (2026). Adipose tissue-derived mesenchymal stem cells — Competitive Intelligence Brief. https://druglandscape.com/ci/adipose-tissue-derived-mesenchymal-stem-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab